SK Biopharmaceuticals Co., Ltd. (KRX: 326030)

SK Biopharmaceuticals Revenue

SK Biopharmaceuticals had revenue of 136.60B KRW in the quarter ending September 30, 2024, with 51.21% growth. This brings the company's revenue in the last twelve months to 511.33B, up 75.77% year-over-year. In the year 2023, SK Biopharmaceuticals had annual revenue of 354.89B with 44.16% growth.

• Revenue (ttm): 511.33B
• Revenue Growth: +75.77%
• P/S Ratio: 15.64
• Revenue / Employee: 2.12B
• Employees: 241
• Market Cap: 7,995.78B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	354.89B	108.71B	44.16%
Dec 31, 2022	246.18B	-172.47B	-41.20%
Dec 31, 2021	418.64B	392.65B	1,510.23%
Dec 31, 2020	26.00B	-97.85B	-79.01%
Dec 31, 2019	123.85B	122.75B	11,172.24%